Stone JH, Wallace Z, Perugino CA, et al. Final Results of an Open Label Phase 2 Study of a Reversible B Cell Inhibitor, Xmab®5871, in IgG4-Related Disease. ACR 2017, abstract 4L.
Neuropsychiatrische lupus bij early- en late-onset SLE: een systematische review en meta-analyse
nov 2023 | SLE